Moviprep (Ascorbic Acid, Sodium Ascorbate, Potassium Chloride, Sodium Chloride, Sodium Sulfate Anhydrous, Macr)

Ascorbic Acid, together with other electrolytes and macrogol, creates an osmotic gradient within the intestinal lumen. This gradient draws water from the surrounding tissues into the bowel, increasing fluid volume and stimulating peristalsis, which leads to accelerated evacuation of fecal matter.

The exact dose of Moviprep is determined by the prescribing clinician based on the patient’s age, weight, renal function and the specific endoscopic procedure. Typically the product is reconstituted with a specified volume of water and taken in divided doses as directed on the prescription label.

Safety of Moviprep in pregnancy and lactation has not been established, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Moviprep product page at gnhindia.com, providing the required quantity and your institutional details. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before responding with pricing, availability, shipping terms and any necessary import documentation.

Compared with sodium‑picosulfate‑based or polyethylene‑glycol‑only preparations, Moviprep combines ascorbic acid with electrolytes to achieve effective cleansing with a lower total fluid volume. It offers similar efficacy to other PEG‑based solutions but may be associated with a different side‑effect profile, such as higher rates of mild nausea, while maintaining comparable safety when used as directed.

Store Moviprep at ambient temperature, below 25 °C, in its original sealed container. Protect the powder from moisture and direct sunlight. Once reconstituted, the solution should be used within the time frame specified in the package insert and any remaining solution should be discarded; do not refrigerate the powder.

Moviprep is supplied as a powder that must be dissolved in a measured amount of clean drinking water, typically 1 L, to create an oral solution. The patient drinks the solution in one or two divided doses, following the timing instructions provided by the prescriber, and should continue to consume additional clear fluids as recommended to maintain hydration.

The most serious adverse events linked to Moviprep include severe dehydration, significant electrolyte disturbances such as hyponatremia or hypokalemia, acute renal impairment, and, rarely, colonic perforation. Patients should be monitored for signs of these conditions, and the preparation should be discontinued immediately if severe symptoms develop, with prompt medical evaluation.

Moviprep is contraindicated in individuals with known or suspected bowel obstruction, perforated gastrointestinal tract, severe inflammatory bowel disease, uncontrolled electrolyte abnormalities, or severe renal insufficiency. It should also be avoided in patients who have had an allergic reaction to any component of the formulation. Use only under medical supervision after appropriate assessment.